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pondence of each voxel with respect to the planning CT. The widely 
applied intensity-based algorithms operate globally on the whole 
image. They are not capable of accurately matching large heteroge-
neous deformations as occur in the bladder area.  
A number of feature-based approaches are used like the Finite Ele-
ment Method (FEM). The FEM describes the forces in the bladder and 
deforms the organs according to urine filling by solving the stress 
equations. Such models are in principle able to yield a good anatomi-
cal correspondence. However, for their best performance they require 
detailed knowledge of the tissue properties which is not yet available. 
A more heuristic approach can be followed by application of the 
Symmetric Thin Plate Spline Robust Point Matching algorithm. Points 
are placed on the surfaces of the volumes that have to be matched. 
Subsequently, the distances of these points are minimized. Recently, 
the algorithm is modified with a weight parameter to allow flexibility 
control of the tumor and bladder wall. They are considered as sepa-
rate structures, with a more flexible bladder. Rather coherent regis-
trations are achieved, with lower marker errors for the modified 
algorithm (Figure). 
It can be concluded that important progress has been made to effec-
tively improve bladder cancer irradiation. An important role is played 
by the cystoscopic guided tumor demarcation to visualize the tumor 
during treatment. Sparing of normal tissue is achieved by the adaptive 
procedures. Improvements have to be achieved for better practical 
support of clinical ART procedures and deformable image registration 
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By using the unique resources for conducting epidemiological research 
that we have in the Nordic countries, facilitated by the existence of 
nationwide population and health registries that can be accessed with 
unique individual identification numbers, several population-based, 
studies have been conducted within the Nordic countries to evaluate 
the impact of cancer therapy at a young age on the health of the 
patients and their offspring.  
Three different population-based, nationwide studies will be pre-
sented as examples of clinical epidemiological studies on late effects 
of childhood cancer with outcome data derived from health registries 
and a ‘gold standard’ approach being used for exposure assessment 
including organ radiation dosimetry: (1) A case–cohort study based on 
the population-based cohort of Danish childhood cancer patients and 
all their children with the purpose to quantify the extent to which 
cancer therapy contributes to genetic disease in the children of 
survivors including chromosomal abnormalities, congenital malforma-
tions, stillbirths, and neonatal deaths as possible indicators of genetic 
damage in the next generation. Preconception radiation doses to the 
gonads, uterus, and pituitary gland and administered chemotherapy 
have been quantified from medical records and related to adverse 
outcomes using a generalized estimating equation model and the 
results will be presented. (2) A greater international collaboration to 
study trans-generational effects of cancer treatment in children and 
adolescents – the Genetic Consequences of Cancer Treatment (GCCT) 
study - currently under way in Denmark, Finland and the USA with a 
similar design but with an increased sample size by adding the 
offspring of cancer survivors diagnosed in early adulthood in both 
Denmark and Finland (www.gcct.org). This study is expected to 
provide more definitive answers to questions about the integrity of 
the germline in human populations that have been exposed to muta-
genic cancer therapy. (3) A large ongoing Adult Life after Childhood 
Cancer in Scandinavia (ALiCCS; www.aliccs.org) study of late effects 
in childhood cancer patients. The Nordic cohort consists of nearly 
33,000 children and adolescents with cancer diagnosed below age 20 
in Denmark, Finland, Iceland, Norway, and Sweden. Morbidity-specific 
incidence and cause-specific mortality in these patients will be com-
pared with that of a combined Nordic cohort of more than 212,000 
population-based comparisons. In a cohort surveillance approach, the 
relative and absolute risks for different chronic diseases in adult 
survivors will be assessed based on discharge diagnoses in national 
patient registries. In the initial phase of this research initiative, 
priority is given to late effects in terms of cardiovascular and pulmo-
nary disorders, endocrine disorders and reproductive failures, 
and renal and gastrointestinal disorders. Based on the findings in this 
screening phase, specific, well-defined outcomes will be investigated 
in case-cohort studies among 5-year survivors in order to investigate 
associations, including dose-response, between specific treatment 
regimens and selected outcomes. Detailed information on chemothe-
rapy including drugs and doses and radiotherapy will be abstracted 
from medical records and for some of the studies organ radiation 
doses from direct and scattered irradiation will be estimated.  
The strengths of these studies include the unbiased ascertainment of 
cancer cases through a search in nationwide cancer registries, com-
plete identification of their children (for offspring studies) and un-
biased identification of population comparisons, and long-term, 
virtually complete follow-up of all study populations. 
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Adverse effects of cancer treatment (normal tissue damage, new 
malignancies) represent well-studied phenomena across the radiation 
disciplines. Novel steps are needed to fully exploit current technical 
opportunities to avoid normal tissue radiation exposure. Pediatric 
oncology represents a good model to illustrate the proposed ap-
proaches. On average pediatric cancer patients have a better progno-
sis than adults, they are exposed to radiotherapy and chemotherapy in 
vulnerable periods of growth and development, treatment field 
delineation can be challenging due to close proximity of surrounding 
organs in small children, and these patients are at potential risk for a 
variety of health problems at different points in their life span.  Valid 
dose effect studies require accurate characterization of radiation dose 
characteristics combined with complete and accurate follow-up for 
health effects, including uniform definitions for such health outcomes. 
 In the past, collaborative groups of pediatric oncologists, epidemiolo-
gists, and radiation oncologists have initiated large observational 
follow-up studies of cancer survivors, to quantify dose effect relation-
ships for chemotherapy and radiotherapy. The professionals who treat 
childhood cancer patients typically follow trial protocols, thus allow-
ing for large, often international, trial based late effects follow up 
studies. These studies seemingly represent rather separate, parallel 
efforts, often using different terminology but seeking answers to 
closely related or identical questions. From a methodologic perspec-
tive, trial based follow-up efforts are based on excellent dose assess-
ment methods but face challenges in achieving uniform and complete 
health outcome follow-up beyond 10 or even 5 yrs post treatment. 
Conversely, observational retrospective follow-up studies typically 
have reasonable or good health outcome data, currently on average 
spanning 30+ yrs of follow-up for the oldest pediatric cancer survivors, 
however, it has remained challenging to accurately describe doses at 
organs at risk according to the standards common (and expected) in 
clinical radiation oncology.  In essence, we need to combine the dose 
estimation standard from clinical trials with the follow-up methods 
applied in observational studies. Several parallel approaches should 
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jointly bring the radiation community closer to that goal:  (1) joint 
evidence-based summaries of late effects scientific evidence (e.g. 
QUANTEC 2010 and pediatric QUANTEC, in progress) to reach a com-
mon standard of terminology across the radiation research disciplines, 
including, radiation oncology, physics, radiobiology, epidemiology, 
biostatistics etc.; (2) reach international consensus about standards 
for  real-time, prospective data registration of patients treated for 
cancer now, by including radiation dose and chemotherapy characte-
ristics , short-term and long-term health outcomes, and set-up such 
registries where feasible. Since such registries cannot, by definition, 
answer questions about long-term  effects, it is essential that we 
strengthen the retrospective study arena as well, by (3) including 
added measures (crude or detailed) of exposed organ volume and 
fractionation to existing retrospective study databases (e.g. de Bruin 
et al 2009) to enable international pooled analyses of joint dose-
volume effects for the very long-term late effects for which outcome 
data are already available. Finally, (4) novel  2D-to-3D dose recon-
struction methods to derive DVH-based doses recently proposed for 
Hodgkin lymphoma survivors (Ng et al 2010) should be validated and 
further developed for more general application in retrospective late 
effects studies to quantify the very long-term dose effect relation-
ships according to current standards of dose estimation. By working 
together more closely we can overcome current gaps between clinical 
radiation oncology and population-based studies.  
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Background: Long-term follow-up of women irradiated for breast 
cancer in both randomised trials and observational studies has re-
vealed that past breast cancer radiotherapy regimens have increased 
the risk of heart disease. Assessment of the relationship between 
heart radiation dose and heart disease requires detailed dosimetry. In 
women irradiated for breast cancer, measures of their cardiac dose 
can be combined with outcome information on subsequent heart 
disease to create dose-response relationships. These can then be used 
to predict the likely cardiac risk for women irradiated today.  
Methods: A large database of internationally used breast cancer 
radiotherapy techniques from the 1950s onwards was compiled using 
information from practising and retired radiation oncologists from 
several different countries, from radiotherapy textbooks, and from 
breast cancer radiotherapy protocols.  
Each breast cancer radiotherapy regimen was reconstructed using 
“virtual simulation” which involved the construction of a virtual 3-
dimensional patient representation using CT scan data from a repre-
sentative patient. Radiotherapy beams were designed and applied to 
this patient representation. Following this, the radiation beam and 
patient information were analysed using a CT planning system. For 
each regimen, dose volume histograms were generated and used to 
calculate a number of different measures of dose including mean dose 
and mean dose in equivalent 2 Gray fractions. Doses were estimated 
for the whole heart and for the three main coronary arteries. The 
main sources of variability associated with the dosimetry method were 
assessed.  
Cardiac doses were applied to women irradiated for breast cancer in 
two different studies. The first study included around 40,000 women 
irradiated in 76 randomised trials of radiotherapy in the Early Breast 
Cancer Trialists’ Collaborative Group Overview. In this study, mean 
heart dose was related to death from heart disease. The second study 
was a case control study including around 2,000 women. It investi-
gated incident ischaemic heart disease (myocardial infarction, coro-
nary revascularisation or death from ischaemic heart disease) in 
population-based registries in Denmark and Sweden. Mean heart 
radiation dose was related to risk of developing a major coronary 
event.  
Results: Radiation fields that were used to treat the internal mamma-
ry lymph nodes delivered the highest mean heart doses, particularly 
for left-sided irradiation. Of the cardiac structures considered, the 
left anterior descending coronary artery generally received the high-
est doses, due to its proximity to the left breast. Assessment of the 
effect of patient anatomy on heart dose showed that, although there 
was some interpatient variability in dose, there was greater dose 
variation between tumour laterality and between different regimens. 
In both the randomised and observational data, the risk of developing 
heart disease increased with increasing mean heart dose. In the 
randomised data, there was a 5% increase in heart death per Gray (SE 
1%, 2p<0.00001). In the population-based data, there was a 7% in-
crease in incident ischaemic heart disease per Gray (95% confidence 
interval 2-13%; 2p=0.0001).  
Conclusions: Virtual simulation and CT planning enable the measure-
ment of detailed estimates of cardiac radiation dose. 
The risk of developing heart disease increases with increasing mean 
heart dose, with no evidence of a threshold below which there is no 
risk. 
For women with no cardiac risk factors a mean heart dose of 1 Gray 
from breast cancer radiotherapy is likely to increase her absolute risk 
of an acute coronary event by around 0.5%, while for a mean heart 
dose of 2 Gray, the increase is likely to be around 1%.  Absolute risk 
increases will be larger for women who are already at increased 
cardiac risk prior to radiotherapy.   
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Brachytherapy (BT) can be used for patients with early-stage head and 
neck cancer (HNC) from different subsites: oropharynx, nasopharynx, 
lip, check, and nasal cavity. 
Until recently, 5-year survival rates for locally-advanced HNC were 
reported to be 40% even with early multimodality approaches. Since 
1990s, the treatment of HNC has changed dramatically. Different 
strategies were implemented in order to improve loco-regional control 
(LRC) and overall survival (OS). However, the improvements in onco-
logic outcomes achieved by these efforts have come at the cost of 
increased toxicity and deterioration of QoL, mostly because of the 
increasing incidence of dysphagia and xerostomia. In order to reduce 
the incidence and severity of these complications and to improve QoL 
without jeopardizing outcomes, highly-conformal RT techniques are 
required.  
Given the increasing incidence of HPV-related oropharyngeal cancer 
(OPC) in the last decades, especially among young patients and the 
ongoing discussion in which group of patients dose escalation of RT is 
really necessary, we will limit our discussion on the potential role of 
dose escalation in patients with OPC.  
Is dose escalation really necessary in patients with OPC? 
In the last decades different new strategies have significantly im-
proved LRC and OS. The 5-year Kaplan-Meier estimate of LC was 78% 
for patients with locally-advanced OPC treated at our institution by 
accelerated scheme of chemo-IMRT. In these patients, feeding-tube 
dependence was needed in 65% and the incidence of grade ≥2 late 
toxicities was 44%. Despite the gains achieved, further improvement 
in oncologic outcomes and reduction of late toxicity is needed in all 
patients with OPC, in particular patients with locally-advanced and 
HPV-negative disease. As a result of using highly conformal RT tech-
niques (IMRT, BT, SRT) and the recent introduction of promising 
imaging techniques to predict the final outcome (DCE-MRI, DWI, and 
FDG-PET), dose escalation of RT become appealing. The implementa-
tion of different image-guided techniques, for instance cone-beam 
CT, will further facilitate such risk-adaptive approach to escalate the 
dose of radiotherapy, when needed.  
The current scheme of the Rotterdam Organ-Function Preservation 
Protocol consists of 46 Gy of (chemo)IMRT to all patients followed by a 
boost using BT or Cyberknife SRT for patients with T1-3N+ or IMRT-
boost for large tumors. The combination of 46 Gy of IMRT followed by 
a BT boost in 167 patients with OPC has resulted in excellent LC-rates 
(94% at 5 years) with low toxicity and satisfactory QoL scores. Only 
26% patients needed tube feeding. Grade ≥2 late xerostomia and 
dysphagia were seen in only 11 % and 8%, respectively. Besides T-
stage, the incidence of LRC was also significantly correlated with HPV-
status (p=0.05) and boost technique (BT, Cyberknife vs. IMRT, 
p<0.001) in our patients.  
Improvements of LRC-rates in high-risk OPC might be achieved by 
escalating the dose of RT to the GTV. Raktoe et al (2012) showed that 
70% of all LFs after RT for OPC were seen in the GTV, suggesting 
radioresistance in these tumor parts and might advocate for escalating 
the dose to the GTV.  
Our group is almost ready to launch a risk-adaptive dose escalation 
protocol for patients with OPC. DWI will be performed at baseline and 
after 40 Gy, in order to predict response on RT. Patients with poor 
response (ADC increase of <25%, compared to baseline threshold) 
would be the target for such dose escalation protocol. According to 
our protocol, OPC-patients receive 22 Gy of PDR-BT. In case of poor 
response to the initial treatment, the dose of the PDR will be esca-
lated from to 30 Gy.  
